stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Net income
Madrigal Pharmaceuticals, Inc.'s net income for fiscal 2025 was −$288.3M, compared with −$465.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$155.5M. Over the past ten years it has ranged from −$465.9M (fiscal 2024) to −$6.8M (fiscal 2015); the current reading is higher than 36% of that period. Madrigal Pharmaceuticals, Inc. ranks 485th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$288.3M | — |
| FY2024 | −$465.9M | — |
| FY2023 | −$373.6M | — |
| FY2022 | −$295.4M | — |
| FY2021 | −$241.8M | — |
| FY2020 | −$202.2M | — |
| FY2019 | −$83.9M | — |
| FY2018 | −$32.8M | — |
| FY2017 | −$31.2M | — |
| FY2016 | −$26.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $55.4M | — |
| Jun 2026 | −$57.9M | — |
| Mar 2026 | −$94.4M | — |
| Dec 2025 | −$58.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on MDGL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement